*Correspondence: Peter Schrder [email protected] This article was submitted to Plant Physiology, a section of the journal Frontiers in Plant Science Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Our findings build on previous research showing high discontinuation rates, particularly among individuals using GLP-1 RAs for weight management ( 10 ), and provide new insights into how and why these medications are stopped in real-world clinical settings
IGFBP-3 is the dominant carrier, responsible for the ternary complex with IGF-1 and the acid-labile subunit that accounts for the large, long-lived circulating IGF-1 pool
The core premise is metabolic selectivity: it activates the lipolytic machinery of fat tissue without engaging the growth hormone receptor or elevating IGF-1
2gi) and improved liver health, leading to decreased hepatic inflammation (Fig
Most do, but the likelihood can vary depending on the specific medication